Genmab (GMAB) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic foundation and growth priorities

• Accelerating business expansion with a strong foundation in team, technology, pipeline, and financials.

• Recent ProfoundBio acquisition adds novel ADC platforms and strengthens the pipeline.

• Focused investment and capital allocation to drive patient outcomes and shareholder value.

• Eight marketed products drive recurring revenues, with Q1 recurring revenue growth of 42%.

• 2024 priorities: launch excellence for EPKINLY and TIVDAK, and advancing mid- to late-stage pipeline, especially EPKINLY GEN1046 and Rina-S.

Pipeline and clinical development updates

• GEN1046 (Acasunlimab) showed 17.5 months median OS in PD-L1+ NSCLC, with manageable safety; phase III to start by year-end.

• Additional data for GEN1046 may be presented at ASCO or World Lung Conference.

• GEN1042 update expected by year-end, with learnings from GEN1046 applied.

• HexaBody-CD38 head-to-head trial with DARZALEX ongoing, data expected by year-end for J&J opt-in decision.

Commercial performance and product launches

• EPKINLY launch strong in US and Japan, driven by efficacy, safety, and subcutaneous administration.

• Rapid access and formulary uptake, with 80% of key US accounts ordering; aiming to expand into broader B-cell malignancies.

• TIVDAK sees 10 consecutive quarters of demand growth, with full approval expected based on innovaTV 301 data.

• TIVDAK's head and neck cancer data show promising response rates; regulatory discussions ongoing.